Phase I study of the combination of MLN9708 and fulvestrant
NCT02384746
This study evaluates the safety and efficacy of the novel combination of the proteasome inhibitor MLN9708 (ixazomib) with the anti-estrogen fulvestrant in patients with advanced ER+ breast cancer that is progressing on fulvestrant.

Reference manuscript

Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant.
Gary Schwartz, Kevin Shee, Bianca Romo, Jonathan Marotti, Alexei Kisselev, Lionel Lewis, Todd Miller.
Oncologist. 2021 Jun;26(6):467-e924. doi: 10.1002/onco.13733. Epub 2021 Mar 18.